Solaris Vaccines, Inc.
Fort Collins, CO
- UEI
- G1P5NEDCERA9
- CAGE
- 97FY7
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3185 Rampart Rd, Fort Collins, CO 80521, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A whole-cell inactivated vaccine for improved protection against tuberculosis - project summary/abstract tuberculosis… | National Institute of Allergy and Infectious Diseases | $543,876 | |
| DHA phase II sbir contract for vacciraptor: high-throughput, continuous flow-through system for psoralen-UVA… | Defense Health Agency | $1,298,431 | |
| DHA sbir phase i vacciraptor: high-throughput, continuous flow-through device for psoralen-UVA inactivation of dengue… | Defense Health Agency | $249,723 | |
| Flu vaccine production using a novel pandemic response and prevention manufacturing method - project summary/abstract… | National Institute of Allergy and Infectious Diseases | $298,891 |
About Solaris Vaccines, Inc.
Solaris Vaccines, Inc. is a small, for-profit biotechnology company located in Fort Collins, Colorado, specializing in innovative vaccine development and inactivation technologies. The company focuses on creating advanced vaccine solutions using a unique photosensitizer (riboflavin) and ultraviolet light method to disrupt pathogen genetic material while preserving antigenic integrity. Through federal contract and grant awards, Solaris Vaccines demonstrates expertise in developing cutting-edge vaccine technologies across multiple infectious disease domains, with a particular emphasis on creating whole-cell inactivated vaccines using advanced scientific approaches.
In terms of federal contract awards, Solaris Vaccines, Inc. has secured Small Business Innovation Research (SBIR) contracts with the Defense Health Agency (DHA). These contracts are specifically focused on developing the "VacciraRptor" technology, a high-throughput, continuous flow-through system for psoralen-UVA inactivation. The company has been awarded two contracts totaling approximately $1.5 million, with the most recent Phase II contract valued at $1,298,431.22 and a performance period extending through November 1, 2027. Both contracts were total small business set-asides, reflecting the company's status as a small business and its innovative research capabilities in vaccine development technologies.
Regarding federal grant awards, Solaris Vaccines, Inc. has received project grants from the National Institute of Allergy and Infectious Diseases (NIAID) focusing on advanced vaccine research. The grants include a $269,874 two-year project to develop SOLAVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis vaccine aimed at improving protection against tuberculosis, with a performance period from August 1, 2025 to July 31, 2027. Another grant focused on developing improved influenza vaccine production methods using their novel Solavax inactivation technology. These grants demonstrate the company's commitment to addressing critical infectious disease challenges through innovative vaccine research, with a particular emphasis on developing more effective, adaptable, and comprehensive vaccine solutions for global health threats.
Quick answers
What is Solaris Vaccines, Inc.'s UEI?
Solaris Vaccines, Inc.'s Unique Entity ID (UEI) in SAM.gov is G1P5NEDCERA9.
What is Solaris Vaccines, Inc.'s CAGE code?
Solaris Vaccines, Inc.'s CAGE code is 97FY7.
What is Solaris Vaccines, Inc.'s primary NAICS code?
Solaris Vaccines, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Solaris Vaccines, Inc. located?
Solaris Vaccines, Inc.'s physical address in SAM.gov is 3185 Rampart Rd, Fort Collins, CO 80521, USA.
Is Solaris Vaccines, Inc. registered in SAM.gov?
Yes. Solaris Vaccines, Inc.'s SAM.gov registration is active through April 28, 2027.
What is Solaris Vaccines, Inc.'s most recent federal award?
Solaris Vaccines, Inc.'s most recent federal grant award is A whole-cell inactivated vaccine for improved protection against tuberculosis - project summary/abstract tuberculosis… (R41AI186746), from National Institute of Allergy and Infectious Diseases, on August 1, 2025.
On GovTribe
See Solaris Vaccines, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors